Neurobo Pharmaceuticals Inc (NRBO)
$1.89
$-0.09
(-4.55%)
As on 29-Jan-2025 09:30EDT
Market cap
$20 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
1.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.4
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$--
-
Face value
--
-
Shares outstanding
8,616,010
10 Years Aggregate
CFO
$-120.93 Mln
EBITDA
$-168.50 Mln
Net Profit
$-166.82 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
| 7.4 | 7.4 | -33.7 | -38.4 | -80.2 | -75.1 | -- |
|
BSE Sensex*
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Neurobo Pharmaceuticals Inc (NRBO)
| -52.4 | -35.6 | -98.0 | -76.8 | -40.0 | -56.8 | -89.7 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Neurobo Pharmaceuticals Inc (NRBO)
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality... as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. The company was formerly known as NeuroBo Pharmaceuticals, Inc. and changed its name to MetaVia Inc. in November 2024. MetaVia Inc. is headquartered in Cambridge, Massachusetts. Read more
-
CEO, President, Principal Executive & Director
Mr. Hyung-Heon Kim
-
CEO, President, Principal Executive & Director
Mr. Hyung-Heon Kim
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Neurobo Pharmaceuticals Inc (NRBO)
What is the current share price of Neurobo Pharmaceuticals Inc (NRBO) Today?
The share price of Neurobo Pharmaceuticals Inc (NRBO) is $1.89 (NASDAQ) as of 29-Jan-2025 09:30 EDT. Neurobo Pharmaceuticals Inc (NRBO) has given a return of -80.17% in the last 3 years.
What is the current PB & PE ratio of Neurobo Pharmaceuticals Inc (NRBO)?
Since, TTM earnings of Neurobo Pharmaceuticals Inc (NRBO) is negative, P/E ratio is not available.
The P/B ratio of Neurobo Pharmaceuticals Inc (NRBO) is 1.32 times as on 29-Jan-2025, a 75 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-- |
-- |
2022 |
-- |
-- |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Neurobo Pharmaceuticals Inc (NRBO)?
The 52-week high and low of Neurobo Pharmaceuticals Inc (NRBO) are Rs -- and Rs -- as of 05-Sep-2026.
What is the market cap of Neurobo Pharmaceuticals Inc (NRBO)?
Neurobo Pharmaceuticals Inc (NRBO) has a market capitalisation of $ 20 Mln as on 29-Jan-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Neurobo Pharmaceuticals Inc (NRBO)?
Before investing in Neurobo Pharmaceuticals Inc (NRBO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.